Soleno Therapeutics (SLNO) Other Operating Expenses (2014 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Other Operating Expenses data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 43.31% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 19.68% increase from a year earlier, with the FY2025 full-year figure at $8.2 million, up 154.04% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $1.7 million, down from $1.7 million in the prior quarter.
• Over the last five years, Other Operating Expenses for SLNO reached as high as $3.0 million in Q1 2025 and fell as low as -$858000.0 in Q1 2022.
• Historically, Other Operating Expenses has averaged $891882.4 across 5 years, with a median of $877000.0 in 2024.
• Across the five-year window, Other Operating Expenses sank 79.7% in 2022 and surged 673.48% in 2023, its largest moves.
• Year by year, Other Operating Expenses stood at -$602000.0 in 2022, then surged by 279.57% to $1.1 million in 2023, then tumbled by 69.75% to $327000.0 in 2024, then surged by 425.08% to $1.7 million in 2025, then decreased by 2.04% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.